Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...
Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...
Novo Nordisk said on Wednesday it would begin selling ... highest-strength doses of the drug through LillyDirect. The lowest dose costs $349 a month and the others cost $499 a month.
Novo Nordisk said Wednesday it will sell Wegovy ... Last week, Eli Lilly lowered the price of its starting dose to $349 a month and added two higher doses for $499 a month, though it hasn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback